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Our purpose was to ut i l ize a donor-speci f ic  sHLA Class 
I ELISA to monitor  damage to heart al lografts caused by 
rejection as an alternat ive to myocardial  biopsy. A group 
of 21 pts (34 serum samples from 14 pts and 63 samples from 
7 pts) were screened for the presence of donor-spec i f ic  HLA 
Class I before and after cardiac transplant using an HLA- 
A2-speci f ic  and/or an HLA-B7 specif ic ELISA. The Ab pairs 
used in the ELISA were: MA2.1 (anti-A2, B57) and CRII-351 
(anti-A2, 28) for detect ing HLA-A2, and ME1 (anti-B7, 27) 
and MB40.2 (anti-B7, 40) for detect ing HLA-B7. 
The results showed: i) consistent release of donor-  
type HLA class i immediately post-Tx (d.l; 15-55 ng/ml) ; 
and 2) a smaller rise (4-20 ng/ml), during b iopsy-proven 
rejection episodes. Both HLA-A2 and HLA-B7 levels rose in 
tandem in patients mismatched for both antigens. Pat ients 
with no rejection showed no evidence of donor ant igen above 
background (<3 ng/ml) after the ist post -operat ive day. 
The major di f f iculty seems to be the problem of 
background react ivity in patients with HLA-A9 (occasional 
cross-react iv i ty with the CRII-351 in A2 ELISA) and with 
certain non-B7, 27 antigens. The technique may be of 
cl inical value in pat ients with low background values (<3 
ng/ml) and to d ist inguish reject ion from systemic infection 
which may not ca.use a rise in donor-spec i f ic  sHLA. 
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We have prepared synthetic peptides corresponding tothe ctl alpha helix of HLA 
class I molecules and tested them for effects on in vitro immune responses. Some 
of these peptides were potent inhibitors of T cell differentiation. We evaluated one 
of these peptides, corresponding to residues 75-84 of HLA-B7, designated Allotrap 
07, on heterotopic heart allograft in rats. Treatment of rats with AUotrap 07 either 
before transplantation r at the time of transplantation caused a slight but significant 
delay in rejection. Animals given AUotrap 07 in combination with a suboptimal 
dose of cyclosporine A maintained their grafts indefinetely. When tolerant animals 
were given a subsequent skin graft from the donor or a third party, they accepted 
the donor derived graft but rejected the third party graft. Adoptive transfer studies 
and investigation ofdonor specific ytotoxic T cell precursors showed that tolerance 
resulted from anergy, and not from clonal deletion of suppressor ceils. Tolerance 
could be induced if the peptide was administered intravenously, orally and to a 
lesser extent by subcutaneous injection. These findings indicate that synthetic 
peptides corresponding to HLA molecules may have important therapeutic effects in 
humans. 
